胰腺导管腺癌的治疗进展  

Progress in treatment of pancreatic ductal adenocarcinoma

作　　者：段睿男 钟翔宇[1] 崔云甫[1] 

机构地区：[1]哈尔滨医科大学附属第二医院胆胰外科,黑龙江省哈尔滨市150086

出　　处：《世界华人消化杂志》2016年第8期1206-1212,共7页World Chinese Journal of Digestology

基　　金：黑龙江省科技攻关基金资助项目;No.GC12C304-1~~

摘　　要：胰腺导管腺癌是一种恶性程度极高的消化系恶性肿瘤,约占胰腺癌发病率的90%.其发病隐匿,进展迅速,治疗效果及预后极差,是预后最差的恶性肿瘤之一.外科手术切除,是目前唯一有效的治疗方法,但遗憾的是,很多患者发现时已是晚期,仅有20%-30%的患者有手术切除的机会,且手术后的平均存活期仍不足2年.目前针对胰腺癌的各种治疗手段仍不甚理想.对于胰腺导管腺癌的总体治疗策略应是以手术为核心、多学科综合协作下的、个体化治疗模式.近年来胰腺导管腺癌的各种治疗手段成为研究的热点,本文就其根治性手术、姑息性手术、介入治疗、辅助治疗等治疗方案的进展作一综述.Pancreatic ductal adenocarcinoma （PDAC） is a malignant tumor of the digestive system with a high degree of malignancy, accounting for about 90% of cases of pancreatic cancer. It has an occult onset and progresses rapidly, with a poor treatment effect and prognosis. It is one of malignant tumors with the worst prognosis. Surgical resection, as the only effective treatment, can be performed in only 20%-30% of patients, and the average period of survival after surgery is still less than 2 years. The main treatment strategy for PDAC are surgery-based individualized treatment modalities under comprehensive multidisciplinary collaboration. Currently, the therapeutic effect on pancreatic cancer is still not satisfactory. In recent years, various treatments for PDAC is becoming a hot spot of research. This article reviews the progress in the treatment of PDAC in terms of radical surgery, palliative surgery, adjuvant therapy, and other treatment opinions.

关 键 词：胰腺 胰腺导管腺癌 治疗 

分 类 号：R735.9[医药卫生—肿瘤]